Rigrodsky & Long, P.A. Investigates Omthera Pharmaceuticals, Inc. Buyout


Rigrodsky & Long, P.A. Investigates Omthera Pharmaceuticals, Inc. Buyout

AstraZeneca PLC offers $12.70 per share to Omthera Pharmaceuticals shareholders

WILMINGTON, Del.--(BUSINESS WIRE)-- Rigrodsky & Long, P.A. of Wilmington, Delaware and New York, announces that it is investigating potential legal claims against the board of directors of Omthera Pharmaceuticals, Inc. ("Omthera") (NASDAQ GM: OMTH), headquartered in Princeton, New Jersey. Rigrodsky & Long is investigating possible breaches of fiduciary duties and other violations of law related to Omthera's entry into an agreement to be acquired by AstraZeneca PLC (NYSE: AZN), a global, innovation-driven biopharmaceutical business, for only $12.70 per share, in a transaction valued at approximately $323 million.

According to the press release announcing the proposed buyout, public shareholders of Omthera will receive $12.70 per share in cash for each share of Omthera they own. The investigation concerns whether Omthera's board of directors failed to adequately shop Omthera and obtain the best possible value for Omthera's shareholders before entering into an agreement with AstraZeneca PLC. According to Yahoo! Finance, at least one analyst has set a price target for Omthera stock at $15.00.

If you own the common stock of Omthera (NASDAQ GM: OMTH) and purchased your shares before May 28, 2013, have information, or would like to learn more about these claims, you can discuss these matters or ask questions with no obligations by contacting Seth Rigrodsky or Peter Allocco at (888) 969-4242; or by e-mail to info@rigrodskylong.com. You can learn more about the Omthera acquisition at the Rigrodsky & Long website at: http://www.rigrodskylong.com/investigations/omthera-pharmaceuticals-inc-omth.

About Rigrodsky & Long, P.A.

Rigrodsky & Long, P.A., with offices in Wilmington, Delaware and Garden City, New York, works on behalf of shareholders in state and federal courts throughout the United States. Rigrodsky & Long regularly litigates corporate class action, shareholder derivative, and direct actions on behalf of institutional investors, individual investors, and consumers. Our legal professionals are experts in shareholders rights and corporate governance litigation and practice in Delaware Chancery Court, state courts, and federal courts throughout the United States.

About Omthera Pharmaceuticals, Inc.

Founded in 2008, Omthera Pharmaceuticals, Inc. is an emerging specialty pharmaceutical company that listed on NASDAQ in April 2013 (NASDAQ GM: OMTH). Led by a team of experts with exceptional experience in developing new therapies for lipid disorders, Omthera is dedicated to developing innovative therapies for the millions of patients who have elevated triglyceride levels and increased risk of cardiovascular disease. Omthera currently has 14 employees based in Princeton, New Jersey.

About AstraZeneca PLC

AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

© 2013 Rigrodsky & Long, P.A. Attorney advertising. Prior results do not guarantee a similar outcome.

Tags: Omthera Pharmaceuticals, OMTH, AstraZeneca PLC, AZN, Rigrodsky & Long

Rigrodsky & Long, P.A.
Seth Rigrodsky
Peter Allocco
Fax: 302-654-7530

KEYWORDS: United States North America Delaware


The article Rigrodsky & Long, P.A. Investigates Omthera Pharmaceuticals, Inc. Buyout originally appeared on Fool.com.

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.